Key result
Hyperlipidemia and oral lipid administration significantly increased amiodarone plasma concentrations (>11-fold) and AUC (1.83-fold after oral doses) while decreasing clearance in rat models.
Why the study?
Does hyperlipidemia or a high-fat meal alter the pharmacokinetics of amiodarone in rat models?
Does hyperlipidemia or a high-fat meal alter the pharmacokinetics of amiodarone in rat models?
Hyperlipidemia and high-fat meals significantly alter the pharmacokinetics of amiodarone in rats, decreasing clearance and increasing bioavailability, which should be considered in food effect studies.
May alter amiodarone PK interpretation in hyperlipidemic rat models; leaves open human translation.
The objective of this study was to examine the effect of a high fat meal and hyperlipidemia on the pharmacokinetic behavior of amiodarone. To evaluate these effects, single doses of amiodarone were administered to rats i.v. (25 mg/kg) or orally (50 mg/kg). Some rats were rendered hyperlipidemic by intraperitoneal doses of poloxamer 407 followed by amiodarone i.v. In other normolipidemic rats, amiodarone was administered i.v. in a fasted state or after the administration of 1% cholesterol in peanut oil. Amiodarone plasma concentrations were considerably (>11-fold) increased in hyperlipidemia. Substantial decreases were noted in the clearance, volume of distribution and unbound fraction (11.6, 23 and 24.7-fold, respectively) in plasma of hyperlipidemic rats. Oral lipid caused a significant increase in plasma AUC(0-infinity) (1.38-fold) and a significant decrease in clearance (1.5-fold) of amiodarone after intravenous doses. Oral consumption of 1% cholesterol in peanut oil significantly increased the plasma AUC (1.83-fold) and bioavailability of amiodarone (1.31-fold) after oral doses. In determining oral bioavailability of lipophilic drugs such as amiodarone in food effect studies, in addition to the increase in absorption of drugs, other factors such as a decrease in clearance due to increases in lipoprotein levels should be taken into account.
No takes yet. Share an insight, caveat, or question.
Shayeganpour et al. (2005) studied Hyperlipidemia and high-fat meal effects on pharmacokinetics. Amiodarone vs. Normolipidemic fasted rats was evaluated on Pharmacokinetic parameters (plasma concentrations, clearance, volume of distribution, AUC, bioavailability). Hyperlipidemia and oral lipid administration significantly increased amiodarone plasma concentrations (>11-fold) and AUC (1.83-fold after oral doses) while decreasing clearance in rat models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: